

Supplementary Table 5: Predicted Strong Affinity Epitopes Specific for d42m1 Regressor Tumours

H-2D^b:

	Peptides		IC ₅₀ (nM)	P	T1	T2	T9
Olf195 (L14M)	YSVTNEFIL (wild-type)		5	●			
	YSVTNEFIM (mutant)		5				
Spnb2 (R913L)	VAVVNQIAR (wild-type)		5305	●	●	●	●
	VAVVNQIAL (mutant)		7				
Tbk1 (G722S)	GGLRNVDCL (wild-type)		36				●
	GSLRNVDCL (mutant)		8				
Fam38a (M134I)	MAGINTDHL (wild-type)		23	●	●	●	●
	IAGINTDHL (mutant)		14				
Cxx1b (D54N)	YMLVDDRTF (wild-type)		4303		●	●	
	YMLVNDRTF (mutant)		14				
H2-Q6 (R142L)	FAYEGRDYI (wild-type)		27	●	●	●	●
	FAYEGLDYI (mutant)		14				
A2m (G777V)	FCLSNDTGL (wild-type)		502	●	●	●	●
	FCLSNDTVL (mutant)		15				
Ubqln4 (R262L)	RALSNLESV (wild-type)		10	●	●	●	
	LALSNLESV (mutant)		24				
Olf1715 (D159N)	VSVVDTTFT (wild-type)		11905	●	●	●	●
	VSVVNTTFT (mutant)		41				
Dst (W4459L)	AMMQWLEKM (wild-type)		108	●	●	●	
	AMMQLEKM (mutant)		45				
Tcl1 (H146N)	AAPSHAAVA (wild-type)		15262	●			●
	AAPSNAAVA (mutant)		48				

H-2K^b:

	Peptides		IC ₅₀ (nM)	P	T1	T2	T9
Gm10577 (W61R)	VTFQYSWV (wild-type)		6	●	●	●	●
	VTFQYSRV (mutant)		2				
Wscd1 (A183G)	RSYVYAGL (wild-type)		2	●	●	●	●
	RSYVYGGL (mutant)		3				
Zdhhc22 (C137Y)	LACLYSMV (wild-type)		683	●	●	●	●
	LAYLYSMV (mutant)		5				
Nckap1 (R917P)	VILSFRSL (wild-type)		4	●	●	●	●
	VILSFPSL (mutant)		5				

H-2K^b (continued):

	Peptides		IC ₅₀ (nM)	P	T1	T2	T9
Olfr1394 (T284N)	VTPMFNPL (wild-type)		6	●	●	●	●
	V <u>N</u> TPMFNPL (mutant)		5				
Epb4.1I4b (H159L)	VGPAYALH (wild-type)		3972	●	●	●	●
	VGPAYALL (mutant)		6				
Vipr2 (F298L)	IVVNFALF (wild-type)		169	●	●	●	●
	IVVNFALL (mutant)		7				
Abca14 (A454G)	SAFLYGLV (wild-type)		8	●	●	●	●
	S <u>G</u> FLYGLV (mutant)		7				
Oog3 (L252M)	VYFIYGNL (wild-type)		6				●
	VYFIY <u>G</u> NM (mutant)		7				
Tmem194 (W245C)	RSYWHYLL (wild-type)		9	●	●	●	●
	RSY <u>C</u> HYLL (mutant)		8				
Tas2r116 (K110N)	SIFYFFKI (wild-type)		36	●	●	●	●
	SIFYFF <u>N</u> I (mutant)		10				
Cntnap3 (G382V)	SSGSYLAL (wild-type)		97			●	
	SS <u>V</u> SYLAL (mutant)		11				
Mettl4-ps1 (P30L)	SGFLYPLV (wild-type)		7	●	●	●	●
	SGFLY <u>L</u> LV (mutant)		13				
Dnmt3a (R732P)	LFFEFYRL (wild-type)		25				●
	LFFEFY <u>P</u> L (mutant)		14				
Pde2a (S542N)	ISIAHSLL (wild-type)		8	●	●	●	●
	I <u>N</u> IAHSLL (mutant)		14				
Got1l1 (L66M)	LDYEYLPL (wild-type)		29				●
	<u>M</u> DYEYLPL (mutant)		14				
Cyp3a41a (V302I)	IVFIFAGY (wild-type)		26			●	
	I <u>I</u> FIFAGY (mutant)		14				
Gm16965 (E82Q)	SSTAYMEL (wild-type)		37	●	●	●	●
	SSTAYM <u>Q</u> L (mutant)		15				
Cyb5r2 (A68T)	VIRAYTPV (wild-type)		28	●			
	VIR <u>T</u> YTPV (mutant)		18				
Atg9a (C519F)	DTCSFAQM (wild-type)		1840	●	●	●	●
	D <u>T</u> FSFAQM (mutant)		19				
Nop56 (G194V)	YGYHFPEL (wild-type)		22		●	●	●
	Y <u>V</u> YHFPEL (mutant)		20				
Ogdh (V420I)	IVYETFHL (wild-type)		35		●	●	●
	I <u>I</u> YETFHL (mutant)		22				

H-2K^b (continued):

	Peptides	IC ₅₀ (nM)	P	T1	T2	T9
Bco2M300I	MYYSMPFL (wild-type)	101	●	●	●	●
	<u>I</u> YYSMPFL (mutant)	24				
Abcd4V196L	SIFGYFIV (wild-type)	70				●
	SIFGYF <u>I</u> L (mutant)	26				
Inpp5dM532L	VSFMFNGT (wild-type)	23	●	●	●	●
	VSF <u>L</u> FNGT (mutant)	28				
Qsox2D654Y	FSSLDMSL (wild-type)	8608	●	●	●	●
	FSS <u>L</u> YMSL (mutant)	28				
Odz2V569F	VSFNTVVL (wild-type)	84	●	●	●	●
	VSFNTV <u>F</u> L (mutant)	29				
Adra1aG315V	IVFWLGYL (wild-type)	28	●	●	●	●
	IVFWL <u>Y</u> YL (mutant)	29				
Tas2r113W206L	SLLI ⁺ FSLW (wild-type)	1743	●	●	●	●
	SLLI ⁺ FS <u>L</u> L (mutant)	30				
Prom1I61M	MVHIFLNV (wild-type)	47	●	●	●	●
	MVH <u>M</u> FLNV (mutant)	31				
Rad9bP281L	SSPQLLPL (wild-type)	78				●
	SS <u>L</u> QLLPL (mutant)	32				
Psrc1R63L	VRFSLGPL (wild-type)	270	●	●	●	●
	V <u>L</u> FSLGPL (mutant)	33				
StambpQ183P	IVQEF ⁺ GKV (wild-type)	90	●	●	●	●
	IV <u>P</u> EF ⁺ GKV (mutant)	34				
Ryr2T1658N	LQFHYHTL (wild-type)	186	●	●		
	LQFHYH <u>N</u> L (mutant)	34				
Camk2bG201R	GVILYILL (wild-type)	219				●
	<u>R</u> VILYILL (mutant)	36				
Thsd1G148V	GVFTTQPL (wild-type)	2830		●	●	●
	<u>V</u> VFTTQPL (mutant)	37				
Olf1104G96C	ISFVGCFV (wild-type)	73	●	●	●	●
	ISFV <u>C</u> CFV (mutant)	40				
Trpc7G654V	VLYGVYNV (wild-type)	186	●	●	●	●
	VLY <u>V</u> VYNV (mutant)	41				
Cacng8G79V	GGLTHSGL (wild-type)	3390	●	●	●	
	<u>V</u> GLTHSGL (mutant)	42				
Grsf1S435C	ITMEYSSS (wild-type)	535	●	●	●	●
	ITMEY <u>S</u> C (mutant)	44				

H-2K^b (continued):

	Peptides	IC ₅₀ (nM)	P	T1	T2	T9
Dnahc17 (M1234I)	IMRDLANL (wild-type)	74		●	●	
	I <u>I</u> RDLANL (mutant)	47				
Olfr1022 (D181V)	INHFYCAD (wild-type)	8258	●			
	INHFYCA <u>V</u> (mutant)	49				
Olfr1366 (L68F)	ANLSLVDL (wild-type)	1667		●		
	ANLS <u>F</u> VDL (mutant)	50				

Supplemental Table 5. Predicted Strong Affinity Epitopes Specific for d42m1 Regressor Tumours. A list of all epitopes that are predicted to bind with strong affinity (i.e. IC₅₀ < 50nM), resulting from mutations present in any regressor tumour samples, but not in any of the progressor tumour samples. The list order is based on the predicted affinity of the mutant epitope to either H-2D^b or H-2K^b, beginning with the strongest predicted binder. Spnb2 is the strongest H-2D^b epitope present in all of the regressor samples. 'P' = parental d42m1; 'T1' = d42m1-T1 clone; 'T2' = d42m1-T2 clone; 'T9' = d42m1-T9 clone; 'Gm10577' corresponds to Ensembl gene product ENSMUSG00000073789; 'Gm16965' corresponds to ENSMUSG00000076702.